NCT05976386View on ClinicalTrials.gov

Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

September 24, 2021

Study Completion Date

September 24, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

Dupilumab (SAR231893)

Injection solution Subcutaneous

Trial Locations (1)

33014

Clinical Pharmacology of Miami-Site Number:8400001, Miami

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT05976386 - Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults | Biotech Hunter | Biotech Hunter